FDA greenlights Bos Sci DES for small-vessel stenting, in-stent restenosis
Boston Scientific has received approval from the FDA to market its Taxus Express2 Atom paclitaxel drug-eluting stent (DES), designed for treating small coronary vessels. 

The Natick, Mass.-based company said it is the only DES approved by the FDA for use in vessels as small as 2.25 mm in diameter.

The agency also approved its Taxus Express2 paclitaxel DES for the treatment of in-stent restenosis in bare-metal stents (BMS).

Boston Scientific plans to launch the product immediately.